The role of systemic and targeted therapies in brain metastases

被引：5

作者：

Franceschi, Enrico ^{[1
]}

Bartolotti, Marco ^{[1
]}

Poggi, Rosalba ^{[1
]}

Di Battista, Monica ^{[1
]}

Palleschi, Dario ^{[1
]}

Brandes, Alba A. ^{[1
]}

机构：

[1] Azienda USL Bologna, Bellaria Maggiore Hosp, Dept Med Oncol, I-40139 Bologna, Italy

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2014年 / 14卷 / 01期

关键词：

BRAF V600E melanoma; brain metastases; EGFR mutations; HER2 breast cancer; target therapy; CELL LUNG-CANCER; LAPATINIB PLUS CAPECITABINE; PHASE-II TRIAL; TYROSINE KINASE INHIBITORS; EARLY BREAST-CANCER; RADIATION-THERAPY; OPEN-LABEL; INTRACRANIAL METASTASES; ADJUVANT TRASTUZUMAB; CEREBRAL METASTASES;

D O I：

10.1586/14737140.2014.856760

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

For many years, brain metastases (BMs) have been considered as the final stage of a disease course and engendered skepticism about the efficacy of treatments. Local treatments, mainly, whole-brain radiotherapy have been the standard of care, whereas chemotherapy has been considered of limited efficacy due to the potential role of blood-brain barrier.

引用

页码：93 / 103

页数：11

共 50 条

[41] Targeted therapies for systemic sclerosis
Christopher P. Denton
Voon H. Ong
Nature Reviews Rheumatology, 2013, 9 : 451 - 464
[42] Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases
Johnson, Adam G.
Ruiz, Jimmy
Hughes, Ryan
Page, Brandi R.
Isom, Scott
Lucas, John T.
McTyre, Emory R.
Houseknecht, Kristin W.
Ayala-Peacock, Diandra N.
Bourland, Daniel J.
Hinson, William H.
Laxton, Adrian W.
Tatter, Stephen B.
Debinski, Waldemar
Watabe, Kounosuke
Chan, Michael D.
ONCOTARGET, 2015, 6 (22) : 18945 - 18955
[43] Improvements in Systemic Therapies for Liver Metastases Will Increase the Role of Locoregional Treatments
Kawaguchi, Yoshikuni
De Bellis, Mario
Panettieri, Elena
Duwe, Gregor
Vauthey, Jean-Nicolas
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2025, 39 (01) : 207 - 220
[44] Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations—Chances and Challenges
Marvin Kuske
Ricarda Rauschenberg
Marlene Garzarolli
Michelle Meredyth-Stewart
Stefan Beissert
Esther G. C. Troost
Oliva Isabella Claudia Glitza
Friedegund Meier
American Journal of Clinical Dermatology, 2018, 19 : 529 - 541
[45] Targeted Therapies for the Treatment of Bone Metastases
Zustovich, Fable
Barsanti, Roberto
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (01)
[46] Investigational Therapies for Brain Metastases
Abd-El-Barr, Muhammad M.
Rahman, Maryam
Rao, Ganesh
NEUROSURGERY CLINICS OF NORTH AMERICA, 2011, 22 (01) : 87 - +
[47] 'HER2-LOW' breast cancer brain metastases: An opportunity for targeted systemic therapies in a high-need patient population
Chehade, R.
Freeman, M.
Jerzak, K.
ANNALS OF ONCOLOGY, 2022, 33 : S145 - S145
[48] Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and Challenges
Kuske, Marvin
Rauschenberg, Ricarda
Garzarolli, Marlene
Meredyth-Stewart, Michelle
Beissert, Stefan
Troost, Esther G. C.
Glitza, Oliva Isabella Claudia
Meier, Friedegund
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (04) : 529 - 541
[49] Incidence of brain metastases in metastatic renal cell carcinoma in the era of targeted therapies.
Bowman, Alex
Le, Tri
Christie, Alana
Brugarolas, James
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[50] Reappraising prognostic factors after SRS/FSRT of brain metastases in the era of targeted therapies
Fink, Christoph A.
Tawk, Bouchra
Hahnemann, Laura
Christopoulos, Petros
Hoerner-Rieber, Juliane
Weykamp, Fabian
Lang, Kristin
Thomas, Michael
Debus, Juergen
Koenig, Laila
RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S816 - S819

← 1 2 3 4 5 →